In a letter to Dr Rejman, Professor Arie Zuckerman stated that despite the projected costs of the screening test, the introduction of screening could not be delayed much beyond FDA approval considering the overall morbidity of chronic non-A non-B Hepatitis (including apparently autoimmune liver disease and hepatocellular carcinoma), and litigation which would be indefensible.